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Abstract: Macrocyclic lactones (MLs) are widely used drugs to treat and prevent parasitic nematode
infections. In many nematode species including a major pathogen of foals, Parascaris univalens,
resistance against MLs is widespread, but the underlying resistance mechanisms and ML penetration
routes into nematodes remain unknown. Here, we examined how the P-glycoprotein efflux pumps,
candidate genes for ML resistance, can modulate drug susceptibility and investigated the role of
active drug ingestion for ML susceptibility in the model nematode Caenorhabditis elegans. Wildtype
or transgenic worms, modified to overexpress P. univalens PGP-9 (Pun-PGP-9) at the intestine or
epidermis, were incubated with ivermectin or moxidectin in the presence (bacteria or serotonin)
or absence (no specific stimulus) of pharyngeal pumping (PP). Active drug ingestion by PP was
identified as an important factor for ivermectin susceptibility, while moxidectin susceptibility was
only moderately affected. Intestinal Pun-PGP-9 expression elicited a protective effect against iver-
mectin and moxidectin only in the presence of PP stimulation. Conversely, epidermal Pun-PGP-9
expression protected against moxidectin regardless of PP and against ivermectin only in the absence
of active drug ingestion. Our results demonstrate the role of active drug ingestion by nematodes
for susceptibility and provide functional evidence for the contribution of P-glycoproteins to ML
resistance in a tissue-specific manner.
Keywords: macrocyclic lactones; nematode; parasitology; P-glycoprotein; drug resistance; macrocyclic
lactones; Caenorhabditis elegans
1. Introduction
The treatment of parasitic nematode infections in animals and humans relies on
chemotherapy, and macrocyclic lactones (MLs) represent the most widely used drug class
in veterinary medicine due to their high efficacy, low toxicity, and broad spectrum of target
parasites [1]. However, drug resistance to MLs is now widespread in parasitic nematodes
of ruminants [2], horses [3], companion animals [4,5], and humans [6]. With over 1.5 billion
infected humans [7] and essentially all domestic animals exposed to nematode infections,
the ongoing development and spread of ML drug resistance is an obstacle to maintaining
health standards. In the pathogenic equine parasite Parascaris univalens, resistance against
MLs is widespread, which poses a health threat to young animals worldwide [8].
In Caenorhabditis elegans and in parasitic nematodes, the primary pharmacological
targets of MLs are the glutamate-gated chloride channels (GluCls) [9,10]. The irreversible
binding of MLs to GluCls leads to a hyperpolarisation of the respective neurons that
control locomotion, pharyngeal pumping, and egg laying, resulting in flaccid paralysis
of the muscles and pharynx [9,10]. However, the underlying resistance mechanisms are
insufficiently understood.
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The ATP-binding-cassette subfamily B member 1 (ABCB1) transporter genes, more
commonly referred to as P-glycoproteins (Pgps), were among the first candidate genes for
ML resistance in parasitic nematodes [11,12] and in C. elegans [13,14]. These xenobiotic
efflux pumps are conserved in eukaryotes and have a broad lipophilic substrate range [15].
Their role in ML resistance has been inferred from observed differences of individual Pgp
expression in association with drug exposure [16] and findings of constitutively high ex-
pression levels in resistant compared to susceptible isolates [11]. Recently, next-generation
sequencing (NGS) approaches allowed the identification of genetic signatures of selec-
tion in close proximity to Pgp loci in resistant and introgressed populations [17–19]. In
addition, several functional studies in C. elegans have provided evidence for an involve-
ment in the ML resistance phenotype. For example, individual Pgp deletion strains, and
silencing or inhibition of Pgps increased ivermectin (IVM) susceptibility [13,14]. How-
ever, our understanding of how Pgps contribute to ML resistance functionally remains
superficial and fragmented. In contrast to mammals, which only possess one (human) to
three (rodents) Pgps, the nematode Pgp gene family comprises a diverse repertoire that
differs between nematodes species [20], e.g., 15 Pgps in C. elegans [21] and 10 Pgps in
Haemonchus contortus [22]. More recently, the Pgp repertoire of P. univalens was completely
deciphered, revealing 10 different Pgp genes with particularly strong expression levels for
Pun-pgp-11.1, Pun-pgp-16.2, and Pun-pgp-9 [23]. Across different species, the pgp-9 gene
lineage has been repeatedly associated with ML resistance in several nematode species
such as cyathostomins [19,24], Teladorsagia circumcincta [18,25], and H. contortus [26] and
is regarded as one of the most relevant candidates for a contribution to ML resistance.
While Pgps are expressed in most tissues, expression is most prominent in the intestine in
different nematode species, including P. univalens and C. elegans [23,27–29]. In addition, the
epidermis (= hypodermis) also exhibits moderate Pgp expression levels in P. univalens [27]
and C. elegans [23], but the tissue-specific function of these genes is unclear.
Many marketed ML derivatives have been shown to exhibit differing pharmacokinet-
ics, efficacies, and chemical properties [1]. Generally, MLs are classified into two groups,
the avermectines (including IVM) and the milbemycins (including moxidectin, MOX), the
latter lacking a polysaccharide side chain at C13 of the lactone ring. This chemical disparity
has been suggested to lead to the differences in the affinity of nematode Pgps for different
ML derivatives [24,30]. In mammals, the main route of ML elimination is the intestine, and
here, Pgps have been shown to play an important role [31]. In contrast, the uptake and
elimination routes of MLs in nematodes and the role of Pgps in these processes remain to be
elucidated. Mammalian Pgps also reduce the permeation of MLs through the blood–brain
barrier and Pgp (i.e., ABCB1 or mdr-1) deficiency causes acute neurotoxicity upon IVM
treatment [32]. In this regard, the capacity of MDR-1 to restrict effective crossing of MOX
and IVM over the barrier varies between IVM and MOX [33].
In the present study, we investigated whether the tissue-specific Pgp expression patterns
in nematodes are relevant for modulation of ML susceptibility. Based on their role in mammals,
we hypothesised that intestinal and epidermal Pgp expression in nematodes can reduce ML
permeability of these tissues. Our objective was to examine the effect of tissue-specific
Pgp overexpression at the intestine and at the epidermis on IVM and MOX susceptibility
using transgenic overexpression of the ML resistance candidate gene Pun-PGP-9 in C. elegans.
Additionally, we took advantage of C. elegans behaviour to induce active drug ingestion by
pharyngeal pumping (PP) in the presence of bacteria [34] or through chemical stimulation of
PP by 5-hydroxytryptamine (5-HT = serotonin) [35], while in turn mostly limiting exposure
to the cuticle–epidermis barrier in the absence of an appropriate PP stimulus [36,37]. Our
results show that active drug ingestion increases susceptibility to IVM considerably and to
MOX only moderately and indicate that both derivatives are taken up by C. elegans via the
intestine and cuticle–epidermis. In both tissues, Pgps have a protective function by reducing
the worms’ susceptibility to IVM and MOX.
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2. Results
2.1. Tissue-Specific Expression Patterns of Pun-PGP-9 in a Cel-pgp-9 Mutant Strain
To address the function of Pun-pgp-9 using C. elegans, the Cel-pgp-9 (tm830) null allele
was used to generate transgenic strains carrying extrachromosomal arrays driving tissue-
specific overexpression of Pun-PGP-9. Two lines, henceforth referred to as intestine-Pgp-9
line 1 (IntPgp-9Ex1) and line 2 (IntPgp-9Ex2), were generated with Pun-PGP-9 expression
driven by the intestine-specific gut esterase 1 promotor (ges-1p) [38] and pharyngeal green
fluorescence protein (GFP) expression. Another line, henceforth addressed as epidermis-
Pgp-9, was generated with Pun-PGP-9 expression driven by an epidermis-specific collagen-
19 promotor (col-19p) [39] and pharyngeal GFP expression (EpiPgp-9Ex1). Finally, a line
serving as the control strain expressing only GFP in the pharynx (myo-2p::gfp) (CtrlEx1)
was generated.
Transcription of Pun-pgp-9 was confirmed by RT-PCR for all Pun-PGP-9 transgenic
strains by amplifying a 1043 bp PCR product, while no PCR product was amplified in
the control strain (Figure 1a). Protein localisation in the epidermis and the intestine were
confirmed by the immunofluorescence detection of a FLAG-tag fused to the NH2-end of
Pun-PGP-9 and visualised using a secondary DyLight405 antibody and confocal microscopy
(Figure 1b–e). Pun-PGP-9 protein expression in intestine-Pgp-9 line 1 appeared intestinal
specific (Figure 1b). At a higher magnification, a strong apical expression was apparent
(Figure 1e). Expression in the epidermis-Pgp-9 strain was detectable in the epidermis
(Figure 1c). Specific blue fluorescence was not visible in the control strain following staining,
while pharyngeal GFP expression was visible, indicating that the antibody staining was
specific to the FLAG-tagged Pun-PGP-9 (Figure 1d).
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Figure 1. Tissue-specific expression of Pun-PGP-9 in Cel-pgp-9 loss-of-function strain, strain tm830. Verification of transcription and
tissue-specific expression. (a) Visible bands for all reverse-transcriptase (RT) PCRs on cDNA templates made from whole-worm
total RNA, and no bands for no RT controls and the control strain. (b–e) Confocal microscope images of tissue-specific expression
patterns of fixed, freeze cracked, and immunofluorescence-stained transgenic adult Caenorhabditis elegans (blue lookup table (LUT),
405 nM excitation), pharyngeal GFP expression (green LUT, 488 nm excitation) and merged images (DIC +405 nM + 488 nM).
Primary antibodies target the FLAG-tag fused to Pun-PGP-9 and the secondary antibody is conjugated with DyLight405.
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Images were acquired with a confocal Eclipse Ti-U inverted research microscope and processed and merged with ImageJ [40].
All scalebars are 100 µm. (b) Immunostaining in the intestine-Pgp-9 line 1 (white arrows indicate the intestine) and GFP
expression at the pharynx. (c) Immunostaining of the epidermis-Pgp-9 strain (white arrows indicate the epidermal
syncytium) and pharyngeal GFP expression. (d) Immunostaining in the control strain and pharyngeal GFP expression. (e)
Higher magnification of the intestine-Pgp-9 strain (white arrow indicates the apical membrane), Pun-PGP-9: Parascaris
univalens P-glycoprotein-9, GFP: green fluorescence protein, DIC: differential interference contrast, int: intestine, vul: vulva,
hyp7: hyp7 syncytium, N2∆CelPgp-9 is tm830 (NBRP) [Cel-pgp-9(-)]; Transgenic strains genotypes: Epidermis-Pgp-9 EpiPgp-
9Ex1 [Cel-pgp-9(-); Cel-col-19p::Pun-pgp-9::FLAG::Cel-unc-54_3′-UTR; Cel-myo-2p::gfp:: Cel-unc-54_3′UTR]; Intestine-Pgp-9
Line 1 IntPgp-9Ex1 [Cel-pgp-9(-); Cel-ges-1p::Pun-pgp-9::FLAG::Celunc-54_3′-UTR; Cel-myo-2p::gfp::Cel-unc-54_3′UTR]; Control
strain CtrlEx1 [Cel-pgp-9(-); Cel-myo-2p::gfp:: Cel-unc-54_3′-UTR].
2.2. Motility Assays in Transgenic and Wildtype Caenorhabditis elegans
All mentioned half-maximal effective concentration (EC50) values, fold changes, and
other parameters calculated from the non-linear regression models as well as p-values from
statistical significance tests are given in Supplementary Table S1 for IVM and Supplemen-
tary Table S2 for MOX and are not specifically referenced in the text.
Motility assays were conducted as described elsewhere [41] with modifications for
the stimulation of PP as schematically summarised in Figure 2a. Prior to drug incubations,
induction of PP by feeding OP50 or 5-HT treatment or the lack of PP in the absence of
a stimulus was confirmed visually under a stereo microscope. By PP stimulation, MLs
dissolved in DMSO within the incubation medium were actively ingested. After an 18–24 h
incubation, the motility of worms incubated without drugs in 1% DMSO (negative, vehicle
control) was tested; neither transgene expression nor induction of pharyngeal pumping
by 5-HT or OP50 significantly influenced motility (Kruskal–Wallis test with Dunn’s post
hoc test) compared to the wildtype (WT, untransformed N2 Bristol strain worms)/OP50−
condition (no PP stimulation) (Figure 2b).
2.2.1. The Effect of Active Drug Ingestion on Ivermectin and Moxidectin Susceptibility
Strikingly, the EC50 for the WT in the OP50+ condition was 11.1-fold lower than in the
absence of OP50 bacteria (Figure 2c). In order to evaluate whether this effect is the result
of potentially confounding factors such as IVM metabolisation by the OP50 bacteria or
starvation, OP50 were substituted by 5-HT in the incubation medium, thereby eliminating
the bacteria and food source but maintaining a stimulus for pharyngeal pumping. This
resulted in an 8.0-fold decrease in the EC50 compared to OP50− to a level just above that
achieved by incubation with OP50 bacteria (Figure 2c).
For MOX, stimulation of PP by OP50 also resulted in overall lower EC50 values than in
the absence of PP (OP50−), but the effect of PP was considerably smaller than that observed
for IVM (Figure 2c,d).
Comparing PP induction by 5-HT+ and OP50+, IVM EC50 values were higher when
stimulated by 5-HT across all strains except intestine-Pgp-9 (all p < 0.05, extra-sum-of-
squares F test, Bonferroni corrected) while MOX EC50 values varied slightly in the control
and WT and were not significantly different in both Pun-PGP-9 expressing strains (both
p > 0.05, extra-sum-of-squares F test, Bonferroni corrected) (Figure 2e).
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Figure 2. Pharyngeal pumping increases ivermectin and moxidectin susceptibility. Effect of pharyngeal pumping (PP)
stimulation by OP50 food bacteria or serotonin in Caenorhabditis elegans on ivermectin and moxidectin susceptibility.
(a) Schematic illustration of the experimental setup with active ingestion and intestine drug exposure by PP stimulation.
(b) Mean thrashes/minute ± standard error of the mean (SEM) in the negative control (no drug, 1% DMSO) between
strains and conditions. Each strain/condition combination was compared to WT OP50− with a Kruskal–Wallis test with
Dunn’s post hoc, and p > 0.05 was considered not significant. (c,d) Ivermectin and moxidectin concentration–response
curves calculated with GraphPad v8.3.0 based on thrashes/minute in the WT strain with n = 36 per concentration spread
equally on three separate days. PP stimulation by OP50 bacteria (OP50+) (black), 4 mM 5-HT (red), or in the absence of a
PP stimulus (OP50−) (blue). Significant differences between half-maximal effective concentration (EC50) were calculated
using the extra-sum-of-squares-F test and Bonferroni correction. (e) Comparison of the effect of PP stimulation by OP50
Escherichia coli food bacteria (red) or 5-HT (black) in different transgenic and wildtype strains. (c–e) All calculated four
parameter non-linear regression models and SEM at each concentration correspond to Supplementary Tables S1 and S2.
Prior to the calculation, the no-drug negative control was set to 0.1 nM and all concentrations were log10 transformed.
On the x-axis, the negative control was visualised as “0 M (no drug)” and separated by a break in the axis. P-values <
0.05 were considered significant and are indicated with an asterisk, while corresponding fold-changes are indicated with
arrows. 5-HT: serotonin/5-hydroxytryptamine; WT: C. elegans N2 Bristol; Control strain genotype CtrlEx1 [Cel-pgp-9(-);
Cel-myo-2p::gfp:: Cel-unc-54_3′-UTR].
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2.2.2. Cel-pgp-9 Loss-of-Function Strain Susceptibility Phenotype in Adult Stage
The control strain, which is the Cel-pgp-9 null mutant (CtrlEx1 [Cel-pgp-9(-); Cel-myo-
2p::gfp:: Cel-unc-54_3′-UTR]), did not exhibit increased susceptibility to IVM or MOX
(Supplementary Figure S1a,b). Serving as a control for extrachromosomal array transgene
expression (pharyngeal GFP expression), the calculated EC50 values in the control strain
matched those of the WT for IVM. Likewise, the control strain’s response to MOX was
similar to that of the WT strain despite minor variations (Supplementary Figure S1c,d).
The control strain was used as a reference for both the Pun-PGP-9 overexpression strains,
epidermis-Pgp-9 and intestine-Pgp-9, as it exhibits the same genetic background and
transgenic extra-chromosomal expression.
2.2.3. The Effect of Epidermal Pun-PGP-9 Expression on Ivermectin and Moxidectin
Susceptibility
Epidermal Pun-PGP-9 expression reduced susceptibility to IVM only in the absence of
PP stimulation but to MOX regardless of PP.
Concerning IVM susceptibility, the epidermis-Pgp-9 line resembled the control strain
in the presence of an OP50 PP stimulus (Figure 3a), but in the absence of a PP stimulus, the
EC50 increased significantly by 2.9-fold compared to the control strain. Similarly, the MOX
EC50 in the absence of PP in the epidermis-Pgp-9 strain was also significantly increased
(Figure 3d). However, significantly increased MOX EC50 values were observed regardless
of PP in this strain (Figure 3b). Notably, the differences to the control strain were only
moderate, i.e., a 1.3-fold in the absence of PP (OP50−) and a 1.3-fold (OP50+) or a 1.5-fold
(5-HT+) increase in the presence of PP stimulation.
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(a–d) Concentration–response curves corresponding to Tables S1 and S2 for ivermectin (a/c) and moxidectin (b/d) in the
absence of a PP stimulus (OP50−) or PP stimulation by serotonin (5-HT+/OP50-) in liquid S-medium. (a–d) show the
control strain’s response for 5-HT+ (black dashed line with triangles) or OP50− (grey dashed line with circles), (a,b) show
the epidermis-Pgp-9 strain for 5-HT+ (dark blue with open squares) or OP50− (orange with rectangles) and (c,d) show the
intestine-Pgp-9 line 1 for 5-HT+ (light blue with open squares) or OP50− (red with rectangles). All concentration–response
curves are based on four-parameter non-linear regression models calculated from the motility response (thrashes/minute)
of 36 synchronised 1-day adults per concentration, and error bars represent standard error of the mean. Prior to calculation,
concentrations were log10 transformed, and the no-drug negative control was set to 0.1 nM. On the x-axis, the negative
control was visualised as “0 M (no drug)” and separated by a break in the axis. Significant differences in EC50 values were
compared using the extra-sum-of-squares-F test and Bonferroni correction; p-values < 0.05 were considered significant and
indicated with an asterisk (*), while corresponding fold-changes are indicated with arrows. Pun-PGP-9: Parascaris univalens
P-glycoprotein-9; N2∆CelPgp-9 is tm830 (NBRP) [Cel-pgp-9(-)]; Transgenic strains genotypes: Epidermis-Pgp-9 EpiPgp-9Ex1
[Cel-pgp-9(-); Cel-col-19p::Pun-pgp-9::FLAG::Cel-unc-54_3′-UTR; Cel-myo-2p::gfp:: Cel-unc-54_3′UTR]; Intestine-Pgp-9 Line 1
IntPgp-9Ex1 [Cel-pgp-9(-); Cel-ges-1p::Pun-pgp-9::FLAG::Celunc-54_3′-UTR; Cel-myo-2p::gfp::Cel-unc-54_3′UTR]; Control strain
CtrlEx1 [Cel-pgp-9(-); Cel-myo-2p::gfp:: Cel-unc-54_3′-UTR].
2.2.4. The Effect of Intestinal Pun-PGP-9 Expression on Ivermectin and Moxidectin
Susceptibility
Intestinal Pun-PGP-9 expression reduced susceptibility to both tested MLs, but this
effect was always dependent on active drug ingestion.
Concerning IVM, intestinal Pun-PGP-9 expression reduced the susceptibility to IVM in
the presence of a PP stimulus compared to the control strain (Figure 3c) in two independent
lines (Supplementary Figure S1c,d). In contrast, IVM EC50 values for both lines were not
significantly different from the control strain when PP was not stimulated (Figure 3c).
MOX EC50 values in the two intestine-Pgp-9 lines were also significantly elevated
when PP was stimulated by OP50 or 5-HT compared to the control strain (Figure 3d).
However, in contrast to IVM, the corresponding fold-changes were considerably smaller
(<1.3-fold). In addition, all MOX EC50 values for the two lines were overall lower than the
MOX EC50 values calculated for the epidermis-Pgp-9 line. In the absence of PP stimulation,
EC50 values did not increase compared to the control strain, which is in line with the
observations for IVM.
2.2.5. A Comparison of Moxidectin and Ivermectin Susceptibility in Transgenic and
Wildtype Strains
Compared to IVM, EC50 values for MOX were generally higher across strains, when PP
was stimulated but lower in the absence of a PP stimulus (Figure 4) as detailed below. For
example, MOX EC50 values in the WT in the presence of PP stimulation were significantly
higher, by 6.7- and 7.6-fold, compared to IVM (Figure 4) for co-incubation with OP50 or
5-HT, respectively. In contrast, when a PP stimulus was not provided, the MOX EC50 was
not significantly different compared to that of IVM (Figure 4). Across strains, only small
fold-changes below 1.2-fold for the MOX EC50 values were detected in the presence or
absence of PP stimulation, which is in a sharp contrast to those for IVM. As for IVM, a
marked EC50 increase (up to 11-fold in WT) from PP stimulation to no PP was observed in
all strains (Figure 4). Likewise, Pun-PGP-9 expression only resulted in low fold changes for
MOX EC50 values (<1.5-fold) in comparison to considerably higher fold changes (e.g., >3.5-
fold in intestine-Pgp-9) for IVM (Figure 4). Despite the marked effect on IVM susceptibility
from intestinal Pun-PGP-9 overexpression, all EC50 values for both intestine-Pgp-9 lines
in the presence of PP stimulation remained lower compared to EC50 values of any other
strain in the absence of a PP stimulus (Figure 4). In contrast, MOX EC50 values in the
intestine-Pgp-9 strains in the presence and absence of PP were similar (Figure 4).
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54_3'-UTR; Cel-myo-2p::gfp:: Cel-unc-54_3’UTR];. Intestine Pgp-9 Line 1 (L1) and Line 2 (L2) geno-
type is IntPgp-9Ex1 or 2 [Cel-pgp-9(-); Cel-ges-1p::Pun-pgp-9::FLAG::Celunc-54_3'-UTR; Cel-myo-
2p::gfp::Cel-unc-54_3’UTR];. Control strain genotype is CtrlEx1 [Cel-pgp-9(-); Cel-myo-2p::gfp::Cel-
unc-54_3'-UTR]; WT is N2 Bristol. Pgp: P-glycoprotein; Pun-PGP-9: Parascaris univalens P-glyco-
protein-9; IVM: ivermectin; MOX: moxidectin; PP: pharyngeal pumping; WT: wildtype. 
2.2.5. A Comparison of Moxidectin and Ivermectin Susceptibility in Transgenic and 
Wildtype Strains 
Compared to IVM, EC50 values for MOX were generally higher across strains, when 
PP was stimulated but lower in the absence of a PP stimulus (Figure 4) as detailed below. 
For example, MOX EC50 values in the WT in the presence of PP stimulation were signifi-
cantly higher, by 6.7- and 7.6-fold, compared to IVM (Figure 4) for co-incubation with 
OP50 or 5-HT, respectively. In contrast, when a PP stimulus was not provided, the MOX 
EC50 was not significantly different compared to that of IVM (Figure 4). Across strains, 
only small fold-changes below 1.2-fold for the MOX EC50 values were detected in the pres-
ence or absence of PP stimulation, which is in a sharp contrast to those for IVM. As for 
IVM, a marked EC50 increase (up to 11-fold in WT) from PP stimulation to no PP was 
observed in all strains (Figure 4). Likewise, Pun-PGP-9 expression only resulted in low 
fold changes for MOX EC50 values (<1.5-fold) in comparison to considerably higher fold 
changes (e.g., >3.5-fold in intestine-Pgp-9) for IVM (Figure 4). Despite the marked effect 
on IVM susceptibility from intestinal Pun-PGP-9 overexpression, all EC50 values for both 
Figure 4. Comparison of moxidectin and ivermectin in wildtype and transgenic Caenorhabditis elegans strains. Forrest
plot visualising the EC50 and corresponding 95% confidence intervals for ivermectin (red) and moxidectin (turquoise) in
transgenic and wildtype Caenorhabditis elegans strains in the presence of pharyngeal pumping (PP) stimulation by OP50 food
bacteria (OP50+) or 5-hydroxytryptamine (5-HT+) or no PP stimulation (OP50−) were visualised using ggplot2 [42] in R
v4.0.3 [43]. EC50 values were inferred from four-parameter linear regression models calculated from 36 synchronised 1-day
adult worms per concentration, strain, and condition using GraphPad v8.3.0. Worms were incubated for 24 h in S-medium
containing a concentration series of ivermectin or moxidectin in a final DMSO concentration of 1%. Epidermis-Pgp-9
genotype is EpiPgp-9Ex1 [Cel-pgp-9(-); Cel-col-19p::Pun-pgp-9::FLAG::Cel-unc-54_3′-UTR; Cel-myo-2p::gfp:: Cel-unc-54_3′UTR];.
Intestine Pgp-9 Line 1 (L1) and Line 2 (L2) genotype is IntPgp-9Ex1 or 2 [Cel-pgp-9(-); Cel-ges-1p::Pun-pgp-9::FLAG::Celunc-
54_3′-UTR; Cel-myo-2p::gfp::Cel-unc-54_3′UTR];. Control strain genotype is CtrlEx1 [Cel-pgp-9(-); Cel-myo-2p::gfp::Cel-unc-
54_3′-UTR]; WT is N2 Bristol. Pgp: P-glycoprotein; Pun-PGP-9: Parascaris univalens P-glycoprotein-9; IVM: ivermectin;
MOX: moxidectin; PP: pharyngeal pumping; WT: wildtype.
3. Discussion
3.1. The Role of Pun-PGP-9 in Ivermectin and Moxidectin Susceptibility
The objective in this study was to elucidate the general functional role of Pgp ex-
pression in specific tissues in the context of ML susceptibility. To this end, we chose to
exemplarily characterise Pun-PGP-9, as it has already been shown to interact with IVM in a
yeast model [23]. An important qu stio addressed in this work was whether there are
ifferences in the protective effect of Pgp overexpression between diff rent ML derivatives,
by testing IVM as an avermectin and MOX as a member of the milbemycins, which are
summarised in Figure 4.
Currently, functional evidence regarding the interaction between specific parasite Pgps
and different MLs has mostly been inferred from indirect assays using the above-mentioned
yeast model [23,24] or the cell line LLC-PK1 [24,29,30,44,45]. In these model systems, MLs
were used as inhibitors for a secondary Pgp substrate with a discernible effect in the model
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systems to characterise the interaction between a transgenic parasite Pgp and different
MLs. These studies have consistently suggested that MOX has a lower affinity to the
examined nematode Pgps than IVM. This conclusion is further supported by our findings
in C. elegans that Pun-PGP-9 overexpression induces larger susceptibility shifts for IVM
than for MOX, which were observed without the use of a secondary substrate. Whether the
low fold-changes for MOX have any biological significance remains to be elucidated [46].
However, Pun-PGP-9 overexpression reduced both MOX and IVM susceptibility, which
indicates that both MLs are probably Pun-PGP-9 substrates. This substrate range could
facilitate cross-resistance, which indeed has been reported in Parascaris sp. [47].
In C. elegans, only one study had previously demonstrated the impact of a trans-
genic Pgp on IVM susceptibility, by overexpressing Pun-PGP-11.1 under the control of
the native Cel-pgp-11 promotor [41], which has been shown to primarily drive intestinal
expression [48]. The concordantly observed moderate fold changes in this and Janssen
et al., despite the extrachromosomal array overexpression, might indicate that Pgps cannot
cause resistance by themselves in parasitic nematodes but rather that Pgps are contributors
within a multigenic context as proposed by NGS studies in other nematode species [17,18].
3.2. The Intestinal and Transcuticlular-Epidermal Uptake of Ivermectin and Moxidectin
Interestingly, the extent of the protective effect against IVM resulting from the Pun-
PGP-9 expression at the intestine or the epidermis was markedly influenced by the selective
intestinal exposure from active drug ingestion by PP. By itself, this newly described effect of
active drug ingestion on ML susceptibility was considerable and, for IVM, even surpassed
the extent of the effect of Pgp overexpression in either tissue.
The differences between the effect on MOX and IVM susceptibility of active drug
ingestion and intestinal or epidermal Pun-PGP-9 overexpression might be interpreted
as differing uptake capacities at specific C. elegans tissues. As a general mechanism, PP
stimulation is required for food uptake, and the increased uptake of incubation fluid also
facilitates the accumulation of its contents [36].
For IVM, the strong effect of active drug ingestion and the PP dependency of the
protective effect of intestinal Pun-PGP-9 expression indicate that higher intestinal exposure
increases the overall concentration and effect of IVM. Nonetheless, the measurable impact
of epidermal Pun-PGP-9 expression on susceptibility also indicates that IVM is taken up,
although less efficiently, via the cuticle–epidermis.
In contrast, the effect of epidermal Pun-PGP-9 expression on MOX susceptibility
regardless of PP could suggest that the epidermis–cuticle is the predominant MOX uptake
route. For IVM and a few other anthelmintics, transcuticular-epidermal permeability
had already been described by biophysical studies on cuticle–epidermis preparations of
Ascaris suum and experiments using live A. suum with a surgically ligated pharynx [49,50].
Likewise, experiments in C. elegans have demonstrated a considerably quicker onset of
pharyngeal paralysis in a cuticle defective C. elegans bus-8 loss-of-function strain [51]. A
study by O’Lone and Campbell indicated that PP inhibition by refrigeration, and thus
inhibition of oral ingestion, reduced the susceptibility to IVM in C. elegans [52]. The authors
suggested that oral ingestion increases IVM susceptibility but that transcuticular-epidermal
uptake is sufficient to induce paralysis at comparatively low concentrations [52], which is
in high concordance with our observations and conclusions.
In contrast to IVM, the uptake of MOX in nematodes has not been studied at all.
The absence of a similarly strong effect of PP on MOX susceptibility as observed for IVM
could indicate that the cuticle–epidermis represents the main MOX penetration route. This
conclusion is also supported by the lowest MOX susceptibility regardless of PP stimulation
in the epidermis-Pgp-9 strain. The main factor determining permeability through the
nematode cuticle is compound size [49,50,53], and MOX is considerably smaller than IVM
due to the lack of the C13 glycosyl side chain. Additionally, lipophilicity is an ancillary but
important factor for transcuticular permeability [49,50,53], and indeed IVM has a lower
lipophilicity than MOX [54]. These differences in size and lipophilicity seem to offer a
Pharmaceuticals 2021, 14, 153 10 of 17
reasonable explanation for a less efficient transcuticular IVM uptake but cannot explain
why intestinal drug exposure from active drug ingestion increased only IVM but not MOX
susceptibility. Therefore, more detailed studies are needed to understand this difference.
Both ML derivatives are very lipophilic and accumulate well in high-fat-content tissues in
the host [55]. In this regard, the mainly intestinal and epidermal fat storage in C. elegans [56]
should facilitate passive diffusion and accumulation in these tissues.
3.3. Experimental Limitations and Relevance for Parasitic Nematodes
The novel insights from the present study are, to some extent, limited to the model
nematode C. elegans that was utilised, since the required forward genetic tools are not yet
available for Parascaris sp. or any related parasitic nematode species [57]. However, it
may be anticipated that the general conclusions of the tissue-specific protective function
in C. elegans may be extrapolated as a general functional mechanism of Pgps in nematode
barrier tissues, such as the epidermis and the intestine, in light of a common nematode
body structure. Nevertheless, it should be noted that parasitic nematodes exhibit differ-
ences in size, life cycle, stage-specific feeding behaviour, genetics, e.g., in their receptor
repertoire [58] and, hence, in their drug susceptibility [59]. For example, IVM and MOX
EC50 values for adult C. elegans were several fold higher than those measured in the adult
stage of examined parasitic nematodes in vitro, e.g., T. circumcincta [60]. The reasons for
these differences remain elusive and have been a matter of speculation. In non-feeding
third larval stages, exposure to MLs (or any other anthelmintic) is restricted to the cuticle
and, indeed, non-feeding larval stages of parasitic nematodes exhibit considerably lower
susceptibilities [60,61]. These differences might be explained by an increased susceptibility
from active IVM ingestion. Furthermore, the sheath (i.e., the residual cuticle of the sec-
ond larval stage) of the third-stage strongylid larva might also reduce susceptibility by
limiting drug penetration into the worm. Regarding the uptake of MLs in adult stages of
parasitic worms, an in vivo study using an ML-resistant population of the sheep parasite
H. contortus found no difference of initial drug accumulation in parasites between MOX,
IVM, and abamectin 0.5 days after treatment [62]. However, MOX concentrations in the
host dropped significantly compared to IVM and abamectin despite similar plasma levels
within 2 days post treatment, suggesting that drug elimination may vary between different
ML derivatives [62]. In Ostertagia ostertagi, a cattle parasite dwelling on the surface of the
abomasal mucosa and feeding by sucking on the mucosa, IVM levels in the worms were
shown to correlate with IVM concentration in the abomasal mucosa and were maximised
by subcutaneous drug application [63]. These findings would support that parasite ne-
matode IVM susceptibility is also increased by feeding. In the same study, IVM levels in
the cattle parasite, Cooperia oncophora, which dwells in the small intestine, correlated well
with intestinal content, and parasite exposure was maximised by oral drug application [63].
Overall, the study by Leathwick et al. highlights how parasite exposure considerably
differs between parasitic species with regard to their biology [63], a concept that can also be
extended to the different developmental stages, e.g., migrating/histotropic or hypobiotic
stages. Based on the feeding behaviour, the blood-sucking H. contortus would be expected
to experience high intestinal ML exposure during the early peak in plasma concentrations
and, thereafter, prolonged low intestinal exposure, while the parasite cuticle would be
exposed from the drug in the abomasal fluid [62,64,65]. Measuring IVM concentrations in
adult H. contortus 3 days after subcutaneous injection, Lloberas et al. reported only a weak
correlation with plasma levels, possibly because of the timing of the measurement [64].
In contrast, intraruminal IVM application resulted in very high abomasal drug concen-
tration, which also resulted in high concentration in the parasite tissues 3 days after IVM
application, suggesting an efficient transcuticular uptake [64].
Regarding the observed tissue-specific expression patterns, some reservations remain
whether expression was exclusive to the targeted tissues, the intestine and the epidermis.
The representative images in Figure 1 show the principal expression pattern differences
observed in the stained worms between the lines with transgenic expression induced by
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two well-characterised promotors, ges-1p and col-19p. However, extrachromosomal array
overexpression might result in background expression in other tissues and in particular epi-
dermal specificity was difficult to verify as fluorescence was visible throughout the worm
and staining appeared variable along the length of all stained worms. The fluorescence
visible in the entire worm might be explained by autofluorescence as it appeared in both the
green and blue channels (Figure 1c). The variability in the strength of the staining was also
observed in other worms and could be the result of a non-uniform antibody exposure and
deformation resulting from the patchy freeze-cracking. 3D-images would be better suited
to verify tissue specificity and to rule out background expression in unwanted tissues [66].
4. Conclusions
Our results demonstrate that Pgps can contribute to reducing ML susceptibility in a tissue-
specific manner in nematodes and that active drug ingestion increases ML susceptibility. The
observed dependency of the protective effect of intestinal or epidermal Pgp overexpression on
active drug ingestion would suggest a role of Pgps in barrier fortification by reducing tissue
drug permeability as a possible mechanism of a Pgp-mediated ML susceptibility as illustrated
in Figure 5. As the tissue-specific expression patterns vary considerably between the diverse
Pgp lineages in different nematode species [23,27], the protective capacity of a specific Pgp
lineage will vary between species and developmental stages.




Figure 5. Schematic illustration of P-glycoprotein-mediated barrier function. Hypothetical sche-
matic illustration of Pgp-mediated barrier function in a Caenorhabditis elegans adult. Expression of 
P-glycoproteins in specific barrier tissues, i.e., the epidermis and the intestine prohibit MLs from 
reaching target tissues, thereby preventing an ML-induced hyperpolarisation of the neurons and 
muscle paralysis.  
5. Materials and Methods 
5.1. Plasmids and Plasmid Construction 
Plasmids for transgenesis were assembled using the NEB HIFI DNA Assembly Kit 
(New England Biolabs Inc.) according to the manufacturer’s instructions into the pUC19 
vector linearised with SmaI (ThermoFisher). Plasmid constructs were Cel-col-19p::Pun-pgp-
9::FLAG::Cel-unc-54_3'-UTR utilising the col-19 promotor [39] to drive epidermal Pun-
PGP-9 expression (Supplementary Figure 3a) and Cel-ges-1p::Pun-pgp-9::FLAG::Cel-unc-
54_3'-UTR (Supplementary Figure 3b) utilising the ges-1 promotor [38] to drive intestine-
specific Pun-PGP-9 expression. The C. elegans unc-54 3'-UTR [41] and the Pun-pgp-9 cDNA 
[23] were amplified from verified plasmids, while the 3' end primer for the Pun-pgp-9 am-
plification introduced an in-frame FLAG-tag (DYKDDDDK) before the stop codon (all 
primers in Supplementary Table S3). The C. elegans promotors col-19p and ges-1p [38] were 
amplified from genomic DNA extracted from the Bristol N2 strain [39]. A co-injection 
Figure 5. Schematic illustration of P-glycoprotein-mediated barrier function. Hyp thetical schematic illustration of Pgp-
mediated barrier function in a Caenorhabditis elegans adult. Expression of P-glycoproteins in specific barrier tissues, i.e., the
epidermis and the intestine prohibit MLs from reaching target tissues, thereby preventing an ML-induced hyperpolarisation
of the neurons and muscle paralysis.
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Furthermore, our findings emphasise that more attention should be placed on how tar-
get parasite species take up ML drugs, since this might lead to differences in susceptibility
to individual ML derivatives. Whether changes in barrier permeability represent a relevant
mechanism of anthelmintic resistance remains to be elucidated in parasitic nematodes.
In conclusion, this study significantly improves the understanding of a Pgp-mediated
ML resistance mechanism by demonstrating how transgenic Pgp expression at specific
barriers can impact the susceptibility to different ML derivatives. Furthermore, the differing
relevance of active drug ingestion for IVM and MOX susceptibility suggests thus far
unknown pharmacological differences and demonstrates the importance of drug barriers
and uptake routes for susceptibility.
5. Materials and Methods
5.1. Plasmids and Plasmid Construction
Plasmids for transgenesis were assembled using the NEB HIFI DNA Assembly Kit
(New England Biolabs Inc., Ipswich, MA, USA) according to the manufacturer’s instruc-
tions into the pUC19 vector linearised with SmaI (ThermoFisher, Waltham, MA, USA).
Plasmid constructs were Cel-col-19p::Pun-pgp-9::FLAG::Cel-unc-54_3′-UTR utilising the col-
19 promotor [39] to drive epidermal Pun-PGP-9 expression (Supplementary Figure S3a) and
Cel-ges-1p::Pun-pgp-9::FLAG::Cel-unc-54_3′-UTR (Supplementary Figure S3b) utilising the
ges-1 promotor [38] to drive intestine-specific Pun-PGP-9 expression. The C. elegans unc-54
3′-UTR [41] and the Pun-pgp-9 cDNA [23] were amplified from verified plasmids, while
the 3′ end primer for the Pun-pgp-9 amplification introduced an in-frame FLAG-tag (DYKD-
DDDK) before the stop codon (all primers in Supplementary Table S3). The C. elegans
promotors col-19p and ges-1p [38] were amplified from genomic DNA extracted from the
Bristol N2 strain [39]. A co-injection marker plasmid (pPD118.33) driving pharyngeal GFP
expression was used (Addgene L3790 plasmid #1596 was a gift from A. Fire). Sequences of
all constructs were confirmed by Sanger-sequencing (LGC Genomics, Hoddesdon, UK).
5.2. Generation of Caenorhabditis elegans Strains and Maintenance
Caenorhabditis elegans WT strain Bristol N2 was obtained from the Caenorhabditis
Genetics Centre (CGC; University of Minnesota, Minneapolis, MN, USA) and the Cel-pgp-9
deletion strain tm830 [Cel-pgp-9(-)] was obtained from the National BioResource Project
(NBRP; Tokyo, Japan). Strains were maintained at 20 ◦C and standard conditions on NGM
plates [67].
Plasmid constructs for intestinal and epidermal Pun-PGP-9 expression were loaded
onto Eppendorf FemtoTips II needles at 25.0 ng/µL along with pPD118.33 as a co-injection
marker at 12.5 ng/µL. Injection into the gonads of 1-day adults of the Cel-pgp-9 deletion
strain was performed using an Eppendorf Femtojet 4 connected to an Eppendorf microma-
nipulator and mounted onto a Leica inverse microscope. Preparation of worms for injection
was carried out as described elsewhere [68]. Additionally, a strain controlling for pharyn-
geal GFP expression and presence of extrachromosomal arrays in general was generated by
injecting only the co-injection marker. Transgenic strains carrying extrachromosomal arrays
IntPgp-9Ex1 and IntPgp-9Ex2 with genotype [Cel-pgp-9(-); Cel-ges-1p::Pun-pgp-9::FLAG::Cel-
unc-54_3′-UTR; Cel-myo-2p::gfp::Cel-unc-54_3’UTR], EpiPgp-9Ex1 with genotype [Cel-pgp-9(-
); Cel-col-19p::Pun-pgp-9::FLAG::Cel-unc-54_3′-UTR; Cel-myo-2p::gfp::Cel-unc-54_3′UTR]) and
CtrlEx1 with genotype [Cel-pgp-9(-); Cel-myo-2p::gfp::Cel-unc-54_3′-UTR) were maintained
by regular transfer of GFP-positive individuals to a new plate.
5.3. Verification of Pun-PGP-9 Expression by RT-PCR and Immunofluorescence
Transcription of Pun-pgp-9 in GFP-positive offspring of injected worms was confirmed
by reverse transcriptase (RT)-PCR (primers and cycle conditions in Supplementary Table
S3) using the S7 Fusion enzyme (Mobidiag) and a cDNA or a no-RT control template. cDNA
was generated from DNAse-treated RNA. In addition, tissue-specific Pun-PGP-9 protein
expression was examined with immunofluorescence. Freeze cracking and antibody staining
were performed in a 1.5 mL tube as described elsewhere [69] with minor adaptations using
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4% formaldehyde and 50% methanol for fixation followed by freeze-cracking worms three
times in liquid nitrogen and thawing in water at room temperature. Following the freeze–
thaw cycles, tubes were shaken at 37 ◦C for 1 h. To remove the fixative, worms were
centrifuged at 11,000× g for 1 min and washed with PBS-T (phosphate-buffered saline
+0.5% Triton-X100) four times, removing all liquid during the last aspiration of PBS-T. Prior
to antibody staining, worms were incubated in 1 mL PBS-BSA (PBS + 1% bovine serum
albumin) overnight at 4 ◦C under mild shaking. The next day, worms were centrifuged for
1 min and then incubated for 24 h at 4 ◦C and mild shaking in 500 µL PBS-BSA containing
a monoclonal (FG4R), mouse-derived anti-FLAG IgG antibody diluted 1:200 (ab125243,
A85282 antibodies.com). The following day, worms were washed again five times in PBS
to remove unbound primary antibody. Once again, worms were incubated for 24 h at 4 ◦C
in 500 µL of PBS-BSA containing DyLight 405 conjugated polyclonal donkey anti-mouse
antibodies diluted 1:300 (DyLight™ 405 AffiniPure Donkey Anti-Mouse IgG (H+L), Jackson
ImmunoResearch). Following another five washes with PBS-BSA, all liquid was completely
removed, and worms were transferred in ~25 µL to an untreated microscope slide. After
adding a drop (~25 µL) of VECTASHIELD® mounting medium and sealing with nail
polish, specimens were examined on an Eclipse Ti-U inverted research confocal microscope
(Nikon, Tokyo, Japan) with a 20× and a 40× objective at excitation wavelength 405 nm
to visualise antibody-specific staining (DyLight405) and 488 nm excitation to visualise
pharyngeal GFP expression. Differential interference contrast (DIC) pictures were taken
to visualise worm anatomy. Images were taken using VisiView 4.3.0 at 16 bit. ImageJ
was used to pseudocolour and merge channels [40]. Fluorescent images at 405 nM and
488 nm excitation wavelength were visualised in the blue or green lookup table (LUT) scale
provided by ImageJ.
5.4. Trashing Assay
To prepare stock solutions, IVM and MOX (Sigma-Aldrich, St. Louis, MI, USA) were
dissolved in DMSO and frozen at −20 ◦C. A saturated 40 mM 5-HT stock solution was
prepared by dissolving serotonin creatinine sulphate monohydrate (Sigma-Aldrich) in
S-medium [67] through vigorous vortexing and was either immediately frozen at −20 ◦C
or used directly.
Bleach-synchronised L1 [67] were grown to adult stage on NGM plates (72 h). One-
day-old adults were washed with S-medium by repeatedly allowing worms to sink to
the bottom of a 15 mL centrifuge tube, discarding, and refilling to remove all bacteria.
The arrest of PP caused by the absence of food was confirmed visually after one hour of
acclimatisation with an inverted microscope. In each individual experiment, 12 worms
(only GFP-positive worms in case of transgenic strains) were transferred into 6-well plates
(Sarstedt) with 2 mL S-medium final volume containing either no OP50 bacteria (OP50−),
OP50 bacteria at OD600 = 0.5 (OP50+) or 4 mM 5-HT (OP50−/5-HT+ referred to as 5-HT+
in the text for simplicity), the latter two stimulating PP, which was visually confirmed
before adding the drug. Dilution series of MLs were prepared in DMSO and added to the
medium resulting in a final concentration of 1% DMSO. For IVM, the final concentrations
for the OP50− condition were 0.0, 10.0, 20.0, 30.0, 40.0, 50.0, and 100.0 nM IVM and for
the OP50+ and 5-HT+ conditions 0.0, 1.0, 2.0, 3.0, 4.0, 5.0, and 10 nM IVM. For MOX, final
concentrations for all conditions were 0.0, 5.0, 10.0, 12.5, 15.0, 17.5, 20.0, 30, 40, 50, and
100 nM MOX. Plates were sealed with parafilm to avoid evaporation and incubated in the
dark at 20 ◦C and 150 rpm for 18–24 h. The next day, worms were transferred by pipetting
to agar-coated Petri dishes filled with S-medium without bacteria and were allowed to
acclimatise for 1 min. Then, thrashes of individual worms were counted for one minute on
a stereo-fluorescence microscope.
Caenorhabditis elegans adult worms that were incubated in S-medium without bacteria
did not readily move, and even soft touch stimulus and shaking did not induce any
movements. However, transfer with a pipette induced strong thrashing, hence this step
was performed across all experiments and all incubation conditions to detect ML-induced
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paralysis. Likewise, adult worms incubated with a sufficient supply of OP50 bacteria only
thrashed occasionally, but the transfer of worms by pipetting induced vigorous thrashing.
5.5. Statistical Analysis
For each concentration, strain, and condition at least 12 worms per day were tested
on three separate days (total n ≥ 36). Before log10 transformation of drug concentrations,
vehicle controls were set to concentrations of 0.1 nM. Four-parameter non-linear logistic
regression models and statistical analyses were calculated and visualised using GraphPad
Prism 8.3.0 (GraphPad Software, San Diego, CA, USA) constraining the bottom values
to ≥0. In each graph, the negative control concentration was visualised as “0 M no
drug” with a break in the x-axis. Forest plots visualising corresponding half-maximal
effective concentration (EC50) and 95% confidence intervals (CI) values were visualised
using ggplot2 [42] in R v4.0.3 [43]. Statistical differences in EC50 values were calculated
with the extra-sum-of-squares F test applying the Bonferroni–Holm correction for multiple
testing and considering a p-value smaller than 0.05 as significant. For comparison, each
Pun-PGP-9-expressing transgenic strain was compared to the control strain at the respective
condition. Moreover, the control strain was compared to the WT at the respective condition.
The EC50 values of the WT at the condition without food (OP50−) and without food plus
5-HT (5-HT+) were compared to the condition with food (OP50+). In addition, statistical
comparisons of EC50 values between MOX and IVM were calculated for the WT. Fold
changes were calculated based on EC50 values. To examine the impact of the feeding
stimuli and transgene expression on motility, the motility response of all worms incubated
without drug (negative no drug controls) were pooled per strain and per condition (n = 72)
and a Kruskal–Wallis test with a Dunn’s post hoc was conducted comparing all conditions
in each strain to the WT OP50− condition in GraphPad.
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-8247/14/2/153/s1, Figure S1: Concentration–response curves for intestine-Pgp-9 Line 2, wild-
type, and control strain; Figure S2: Concentration–response curves of Parascaris univalens Pgp-9-
expressing transgenic, control, and wildtype strains to ivermectin and moxidectin under different
conditions; Figure S3: Vector maps of expression vectors, Table S1 Ivermectin concentration-response
parameters of transgenic, control and wildtype strains at different conditions; Table S2 Moxidectin
concentration-response parameters of transgenic, control and wildtype strains at different conditions;
Table S3: Primer.
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